Trial Profile

CREST UK: CPX-351 Real-World Effectiveness and Safety Study

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 Jan 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms CREST UK
Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

13 Dec 2022 Results from one cohort of this study reporting safety and efficacy data in the context of the COVID-19 pandemic presented at the 64th American Society of Hematology Annual Meeting and Exposition
08 Jul 2022 Status changed from recruiting to completed.
20 Jan 2022 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com